Corporate Presentation

Roberto BelliniPresident and Chief Executive Officer

June 2012

Forward Looking Statement

Certain statements contained in this presentation, other than statements of fact that areindependently verifiable at the date hereof, may constitute forward-looking statements. Suchstatements, based as they are on the current expectations of management, inherently involvenumerous risks and uncertainties, known and unknown, many of which are beyond BELLUSHealth Inc.'s control. Such risks include but are not limited to: the ability to obtain financingimmediately in current markets, the impact of general economic conditions, general conditionsin the pharmaceutical and/or nutraceuticals industry, changes in the regulatory environment inthe jurisdictions in which the BELLUS Health Group does business, stock market volatility,fluctuations in costs, and changes to the competitive environment due to consolidation,achievement of forecasted burn rate, and that actual results may vary once the final andachievement of forecasted burn rate, and that actual results may vary once the final andquality-controlled verification of data and analyses has been completed.

Consequently, actual future results may differ materially from the anticipated results expressedin the forward-looking statements. The reader should not place undue reliance, if any, on anyforward-looking statements included in this news release. These statements speak only as ofthe date made and BELLUS Health Inc. is under no obligation and disavows any intention toupdate or revise such statements as a result of any event, circumstances or otherwise, unlessrequired by applicable legislation or regulation. Please see the Company’s public fillingsincluding the Annual Information Form of BELLUS Health Inc. for further risk factors that mightaffect the BELLUS Health Group and its business

2

Background and Business Model

Public company (TSX: BLU) based in Montreal, QC

Focused namely on the development of products in amyloid-related fields, principally AA Amyloidosis, an orphan indication affecting the kidneys

Late-stage product pipeline

Focused on building value for clinical stage health products in critical unmet

medical needs

BUSINESS MODEL

3

Pipeline of Products

PHARMACEUTICALS

NRM8499

Alzheimer’s

DISCOVERY PRECLINICAL PHASE I PHASE II PHASE III NDA/MAA

Eprodisate

(KIACTA™)

AA amyloidosis

NUTRACEUTICAL

Alzheimer’s

disease

Homotaurine VIVIMIND™

Memory protection

COMMERCIA

-LIZATIONDISCOVERY PRECLINICAL PHASE I PHASE II PHASE III

4

KIACTA™

Phase II/III clinical trial showing statistically

Orphan population of ≈50,000 in the USA, Europe and Japan with peak annual revenues projected at $400-600M1

1 Independent market assessment by Frankel Group in April 2009.

For AA Amyloidosis, an orphan indication and a deadly disease with no treatment

Market opportunity

Clinical

5

Phase II/III clinical trial showing statistically significant primary efficacy endpoints(p value = 0.025) and clean safety profile

Clinical evidence

Partnership with Celtic Therapeutics to conduct and finance confirmatory phase III clinical trialPartnership

Confirmatory phase III

clinical trial

Marketing approval based on confirming safety and efficacy of phase II/III study

Actively recruiting patients

AA Amyloidosis

Rare and life-threatening disease

Associated with chronic inflammatory diseases

� 65% of patients are rheumatoid arthritis patients

AA protein accumulates in major organs, mainly kidneys, leading to:

� Rapid and significant deterioration of kidney function, and

� Eventual progress to dialysis

Kiacta slows the deterioration of kidney function by preventing amyloid A protein fibril formation, accumulation and deposition

� Orally bioavailable small molecule

6

Na+-03S S03-Na+

KIACTA™ - Targeted OpportunityD

iagn

osed

AA

Pat

ient

s (0

00s)

Patient population estimated at 34-50,000 in the U.S., EU5 and Japan1

Clear pharmacoeconomic rationale for premium pricing

™

7

Dia

gnos

ed A

A P

atie

nts

(000

s)

KIACTA™ peak annual revenues projected at $400-600M1

(U.S., EU5, Japan)

Orphan Drug Status in the U.S. and EU provides 7 and 10 years market exclusivity upon commercialization, respectively

1Independent market assessment by Frankel Group in April 2009

FINANCIAL IMPLICATION

With global fund Celtic Therapeutics

Celtic Therapeutics funding 100% of KIACTA™’s

PARTNERSHIP

US$10M in upfront payments

≥ US$35M in investments by Celtic Therapeutics

KIACTA™ - Strategic Partnership

100% of KIACTA™’s confirmatory phase III clinical trial

Auction process for the commercialization rights of KIACTA™ on completion of Phase III clinical trial

Proceeds of any eventual transaction expected to be shared 50%-50% between BELLUS Health and Celtic Therapeutics

8

KIACTA™ - Robust Clinical Results in Phase II/III

Statistical significant on primary endpoint (p value <0.05) and clinically meaningful treatment effect (42% reduction in risk)

� Calculated 2-year delay to dialysis for patients on KIACTATM

Number of

Clean safety profile

Agreement with FDA/EMEA for confirmatory phase III clinical trial

� Marketing approval based on positive result (p value <0.05) from confirmatory study with same scope of first phase III clinical trial

9

Number of

EventsRelative Risk

NC-503 Placebo HR 95% C.I. P value

Primary composite endpoint(First “worse” event)

29 45 0.58 0.37, 0.93 0.025

Doubling SCr 9 17 0.41 0.19, 0.86 0.019

50% decrease CrCl 19 31 0.48 0.28, 0.82 0.008

Dialysis/ESRD 7 13 0.54 0.22, 1.37 0.20

Death 5 5 0.95 0.27, 3.29 0.94

CONFIRMATORY PHASE III STUDY

183 patients in 13 countries

Statistically significant composite primary endpoint (p=0.025) principally based on patients reaching kidney function events:

� Doubling serum creatinine

COMPLETED PHASE II/III STUDY

230 patients in 28 countries

Composite primary endpoint (target p<0.05) based on patients reaching kidney function events:

� 80% increase serum creatinine

KIACTA™ - Confirmatory Phase III Study

� Doubling serum creatinine

� 50% decrease in creatinine clearance

� Reaching ESRD/dialysis

� Death

Fixed treatment duration of 2 years

� 40% decrease in creatinine clearance

� Reaching ESRD/dialysis

Event driven trial to conclude on attainment of 120 events (~90% power)

10

Key improvements made to increase robustness of

confirmatory study

Key improvements made to increase robustness of

confirmatory study

KIACTA™ - Study Progress

Recruitment 1

>70 sites in 26 countries actively recruiting

Completion

Event driven trial to complete on reaching 120 eventsrecruiting

90 patients enrolled

Recruitment expected to be completed in 2H 2013

11

120 events

Study expected to be completed in 2H 2015

Patient baseline characteristics and demographics t o date are similar to those in the first Phase III study

1 Data as of May 10, 2012

KIACTA™ - Providing Base Value

+

DEVELOPMENT COST FULLY FUNDED BY

CELTIC

AUCTION PROCESS WITH

EQUALLY SHARED

PROCEEDS

LOW RISKCONFIRMATORYPHASE III STUDY

12

SIGNIFICANT SHAREHOLDER VALUE BASE

+

VIVIMIND™

Nutraceutical for memory protection

Canada: Protects the hippocampus

Italy: Enhances cognitive function and memoryHealth Claims

Growing cash flow positive business

Partnerships for Italy, Canada, Greece, Middle East and IsraelPursuing efforts to conclude additional partnerships in other territories: creating a distributor network worldwide

Regulatory approvals in Italy and Spain obtained in 2009

NPN number issued by Health Canada in 2010

Regulatory Approval

Partnerships

13

NRM8499

Next generation of tramiprosate intended for the treatment of Alzheimer's disease

Large and growing epidemic currently affecting over 30M patients worldwide

Represents > $180B in annual costs in the USA alone

Market opportunity

14

alone

Completed in 67 young and elderly healthy subjects

Safe and well tolerated at the intended therapeutic dose

Better gastrointestinal tolerability and pharmacokinetic profile than tramiprosate

Company seeking a potential partnership to pursue development process

Phase I clinical trial

Pharmascience

Leading Canadian manufacturer of generic drugs

Private company

Strategic Investment

$17.25M total investment:

� $8.15M in non-dilutive capital

� $9.1M for 10.4% stake

Strategic Partnership and Financing

Annual sales >$700M

R&D budget >$30M

More than 1,300 employees

� $9.1M for 10.4% stake

1 board member

15

Pharmascience transaction closed on May 25 th

Capital Structure

Financial Position and Capital Structure

Basic Shares Outstanding 47M

Fully Diluted Shares Outstanding 61M

Cash (as of May 31 st, 2012) >$20M

Financial Position

1616

Cash (as of May 31 st, 2012) >$20M

Burn Rate (monthly) <$300K

Operations funded beyond 2016

� Kiacta Phase 3 data expected in 2015

� Additional funds can be used for new potential projects

Governance and Shareholders

Board of Directors Company / Experience

Dr. Francesco Bellini (Chair)

Franklin Berger

Charles Cavell

Hélène Fortin

Management Title

Roberto BelliniPresident and Chief Executive Officer

Dr. Denis GarceauSenior Vice President, Drug Development

François Desjardins Vice President, Finance

Tony MatzouranisVice President, Business Development

LAROSE FORTIN CA Inc.

17

Hélène Fortin

Pierre Larochelle

Donald Olds

Joseph Rus

Dr. Martin Tolar

Roberto Bellini

Development

Shareholder Ownership

Bellini Family ≈ 30%

Power Corporation ≈ 30%

Pharmascience ≈ 10%

LAROSE FORTIN CA Inc.

Milestones

Past Execution

Attractive partnership with Celtic for Kiacta

Execution of global Kiacta Phase III

2012 Milestones

Continued execution of KIACTA Confirmatory phase III clinical trial:

Launch of Japan sites and receipt of Japanese orphan drug designation

Long Term Value

Results of confirmatory phase III clinical trial and auction of KIACTA™

18

Short-term milestones driving long-term value

Kiacta Phase III confirmatory study

Building cashflow positive VIVIMIND business

Fully financed business plan

orphan drug designation

Partnership for NRM8499 for Phase 2 study

Financial partner with no shareholder dilution

Large regional partnership for VIVIMIND™

Sale or spin-out of nutraceutical business

NRM8499 Phase 2 study results